Version history

{
  "session_id": "sess_SDA-2026-04-26-gap-20260425-225305_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"SCFA Deficiency Drives Microglial Hyperactivation via GPR43/NF-κB Dysregulation\",\n      \"description\": \"Gut dysbiosis depletes butyrate-producing commensals (Faecalibacterium prausnitzii, Clostridium XIVa, Akkermansia muciniphila), reducing SCFA-mediated activation of microglial GPR43/GPR41 receptors and HDAC inhibition. This removes inhibitory checkpoints on NF-κB, permitting unchecked pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6). The pathway integrates receptor-mediated G-protein signaling with epigenetic regulation through histone deacetylase inhibition, creating a dual braking mechanism on microglial activation that is compromised in neurodegeneration.\",\n      \"target_gene\": \"GPR43 (FFAR2), GPR41 (FFAR3), HDAC3, RELA (NF-κB p65)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.82,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.62,\n        \"therapeutic_potential\": 0.75,\n        \"mechanistic_plausibility\": 0.80,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.65,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.72,\n        \"reproducibility\": 0.68\n      },\n      \"composite_score\": 0.71,\n      \"evidence_for\": [\n        {\"claim\": \"Germ-free mice show defective microglial maturation rescued by SCFA supplementation\", \"pmid\": \"26268901\"},\n        {\"claim\": \"Butyrate administration reduces Aβ plaque burden and improves cognition in Alzheimer's models\", \"pmid\": \"26734968\"},\n        {\"claim\": \"SCFAs suppress LPS-induced TNF-α via GPR41/GPR43\", \"pmid\": \"21383957\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Propionate can be pro-inflammatory in human astrocytes at systemic concentrations\", \"pmid\": \"Haghikia et al., 2016\"},\n        {\"claim\": \"Brain SCFA levels are unconfirmed; first-pass hepatic metabolism limits CNS exposure\", \"pmid\": \"Domain Expert assessment\"},\n        {\"claim\": \"GPR43 expression on microglia in vivo is sparse and context-dependent\", \"pmid\": \"Skeptic critique\"}\n      ]\n    },\n    {\n      \"title\": \"Leaky Gut LPS Translocation Activates Systemic TLR4/MyD88 Signaling, Driving CNS Monocyte Infiltration\",\n      \"description\": \"Dysbiosis compromises intestinal tight junctions (occludin, claudin-1, ZO-1) and reduces α-defensin production, permitting Gram-negative bacteria and LPS translocation into systemic circulation. Circulating LPS engages TLR4 on Kupffer cells and bone marrow monocytes, establishing chronic endotoxemia. MyD88-dependent signaling induces CCL2 (MCP-1), recruiting CCR2+ pro-inflammatory monocytes across the compromised blood-brain barrier into CNS parenchyma, where they amplify neurodegeneration.\",\n      \"target_gene\": \"TLR4, MyD88, IRAK4, CCL2, CCR2, ZO-1 (TJP1)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.78,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.58,\n        \"therapeutic_potential\": 0.72,\n        \"mechanistic_plausibility\": 0.74,\n        \"druggability\": 0.60,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.62,\n        \"data_availability\": 0.68,\n        \"reproducibility\": 0.65\n      },\n      \"composite_score\": 0.67,\n      \"evidence_for\": [\n        {\"claim\": \"Increased intestinal permeability documented in Parkinson's disease patients and α-synuclein transgenic mice\", \"pmid\": \"30929736\"},\n        {\"claim\": \"Circulating LPS correlates with disease severity in Alzheimer's disease\", \"pmid\": \"18785108\"},\n        {\"claim\": \"Blocking CCL2 reduces microglial activation and dopaminergic neuron loss in MPTP models\", \"pmid\": \"16914660\"},\n        {\"claim\": \"MyD88 deficiency protects against neurodegeneration\", \"pmid\": \"21829344\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TLR4 antagonists failed in sepsis; regulatory stigma exists\", \"pmid\": \"Domain Expert assessment\"},\n        {\"claim\": \"Germ-free mice paradoxically show enhanced neuroinflammatory susceptibility\", \"pmid\": \"Erny et al., 2015\"},\n        {\"claim\": \"Modern single-cell studies attribute DAM signature to resident microglia, not infiltrating monocytes\", \"pmid\": \"Skeptic critique\"}\n      ]\n    },\n    {\n      \"title\": \"Butyrate-Producing Commensal Depletion Creates Vicious Cycle: HDAC3 Overactivity Permits TREM2-Independent Microglial Dysfunction\",\n      \"description\": \"Butyrate acts as a pan-HDAC inhibitor suppressing microglial HDAC3 activity. In dysbiosis, butyrate deficiency permits HDAC3 to deacetylate histones at the TREM2 promoter, downregulating TREM2 expression. This exacerbates the TREM2 loss-of-function AD risk phenotype (rs75932628), leading to impaired phagocytosis of Aβ/α-synuclein and metabolic microglial dysfunction (enhanced glycolysis, mitochondrial fragmentation). Undegraded aggregates further stimulate TLR pathways, completing a feedforward inflammatory loop.\",\n      \"target_gene\": \"HDAC3, TREM2, PGC-1α, NLRP3, HIF1α\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.72,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.68,\n        \"mechanistic_plausibility\": 0.70,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.50,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.60\n      },\n      \"composite_score\": 0.63,\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 R47H variant confers AD risk comparable to APOE4\", \"pmid\": \"27523554\"},\n        {\"claim\": \"HDAC3 inhibition promotes TREM2-independent microglial anti-inflammatory genes\", \"pmid\": \"33208957\"},\n        {\"claim\": \"Butyrate reduces Aβ accumulation via microglial epigenetic modulation\", \"pmid\": \"31277771\"},\n        {\"claim\": \"Trem2 knockdown mice exhibit defective amyloid clearance\", \"pmid\": \"25472853\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TREM2 protein levels in human AD show variable results; downregulation not consistent\", \"pmid\": \"Skeptic critique\"},\n        {\"claim\": \"HDAC3 selective inhibitors (RGFP966) have poor CNS penetration\", \"pmid\": \"Domain Expert assessment\"},\n        {\"claim\": \"Butyrate may act via TREM2-independent pathways; Trem2−/− mice should be refractory to butyrate if hypothesis is correct\", \"pmid\": \"Skeptic falsification test\"}\n      ]\n    },\n    {\n      \"title\": \"NLRP3 Inflammasome Priming Converts SCFA-Sensitive Pyroptosis into Chronic IL-1β-Mediated Synaptic Pruning\",\n      \"description\": \"Gut-derived bacterial components (LPS, MDP) provide Signal 1 for NLRP3 inflammasome priming via TLR4/TLR2/NOD2, inducing pro-IL-1β and NLRP3 transcription. Signal 2 activation occurs through mitochondrial dysfunction from SCFA deficiency, causing ROS release and potassium efflux. Active caspase-1 cleaves pro-IL-1β and gasdermin D, executing pyroptotic cell death. Released IL-1β acts on neuronal IL-1R1 to promote complement C1q/C3-mediated synaptic pruning. SCFAs interrupt at both signals via GPR109A-mediated mitochondrial biogenesis and NF-κB inhibition.\",\n      \"target_gene\": \"NLRP3, CASP1, GSDMD, IL1B, IL1R1, C3, C1QA, GPR109A (HCAR2)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.70,\n        \"novelty\": 0.68,\n        \"feasibility\": 0.52,\n        \"therapeutic_potential\": 0.70,\n        \"mechanistic_plausibility\": 0.68,\n        \"druggability\": 0.62,\n        \"safety_profile\": 0.58,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.58\n      },\n      \"composite_score\": 0.62,\n      \"evidence_for\": [\n        {\"claim\": \"NLRP3−/− mice protected against Aβ pathology and cognitive decline\", \"pmid\": \"22989199\"},\n        {\"claim\": \"Gasdermin D-mediated pyroptosis elevated in AD patient brains\", \"pmid\": \"33916204\"},\n        {\"claim\": \"SCFAs suppress NLRP3 inflammasome in metabolic inflammation\", \"pmid\": \"28139699\"},\n        {\"claim\": \"IL-1β drives complement-dependent synapse loss\", \"pmid\": \"26337542\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"GPR109A is highly expressed in colon/retina; brain expression is low and microglial role is unsupported\", \"pmid\": \"Skeptic critique\"},\n        {\"claim\": \"Direct evidence that NLRP3-derived IL-1β specifically upregulates neuronal complement is lacking\", \"pmid\": \"Skeptic critique\"}\n      ]\n    },\n    {\n      \"title\": \"TLR2 Recognition of Gut-Derived Fungal and Bacterial D-Alanylated Lipoteichoic Acid Primes Astroglial NFAT/COX-2 Neurotoxicity\",\n      \"description\": \"Dysbiosis permits overgrowth of SIBO species and opportunistic fungi (Candida albicans, Malassezia) whose cell wall components (D-alanyl-LTA, zymosan) are potent TLR2 ligands. TLR2/MyD88 signaling in astrocytes triggers PLA2-dependent arachidonic acid release, upregulating COX-2/PGE2 and NFAT dephosphorylation. This astrocyte 'priming' converts astrocytes from neurotrophic to neurotoxic, producing complement C3 that tags neurons for phagocytosis by hyperactive microglia.\",\n      \"target_gene\": \"TLR2, MyD88, NFATC1, PTGS2 (COX-2), PTGER2 (EP2), C3\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.58,\n        \"mechanistic_plausibility\": 0.60,\n        \"druggability\": 0.40,\n        \"safety_profile\": 0.52,\n        \"competitive_landscape\": 0.48,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.52\n      },\n      \"composite_score\": 0.55,\n      \"evidence_for\": [\n        {\"claim\": \"TLR2 activation by LTA induces pro-inflammatory COX-2 and PGE2 in astrocytes\", \"pmid\": \"17336429\"},\n        {\"claim\": \"Astrocytic COX-2 overexpression is an early event in AD\", \"pmid\": \"10869346\"},\n        {\"claim\": \"C3a receptor on microglia mediates complement-dependent synaptic loss\", \"pmid\": \"28934326\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TLR2 knockout mice show WORSE outcomes in some neurodegeneration models; protective role exists\", \"pmid\": \"Richard et al., 2018\"},\n        {\"claim\": \"Candida overgrowth associated with IBD and immunosuppression, not typical AD/PD\", \"pmid\": \"Skeptic critique\"},\n        {\"claim\": \"No clinical-stage TLR2 antagonists; NFAT is undruggable\", \"pmid\": \"Domain Expert assessment\"}\n      ]\n    },\n    {\n      \"title\": \"Gut Bacterial Metabolite-AhR Dysregulation Converts SCFA-Deficiency into IDO1-Driven Kynurenine Neurotoxicity\",\n      \"description\": \"Aryl hydrocarbon receptor (AhR), expressed in microglia, astrocytes, and neurons, normally ligates tryptophan catabolites from gut bacteria (indole, indole-3-propionate). Dysbiosis depletes tryptophan-metabolizing commensals, reducing AhR ligand availability. Simultaneously, chronic neuroinflammation elevates IDO1, shunting tryptophan toward kynurenine pathway, producing quinolinic acid (NMDAR agonist) and ROS. SCFAs normally suppress IDO1 via GPR41/GPR43-STAT3 signaling, creating a protective deficit.\",\n      \"target_gene\": \"AHR, IDO1, KYNU, HAAO, GRIN2A, STAT3\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.65,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.60,\n        \"mechanistic_plausibility\": 0.62,\n        \"druggability\": 0.52,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.45,\n        \"data_availability\": 0.58,\n        \"reproducibility\": 0.55\n      },\n      \"composite_score\": 0.58,\n      \"evidence_for\": [\n        {\"claim\": \"AhR deficiency in microglia exacerbates neuroinflammation\", \"pmid\": \"31988383\"},\n        {\"claim\": \"IDO1 activation correlates with CSF kynurenine in AD patients\", \"pmid\": \"25423376\"},\n        {\"claim\": \"Quinolinic acid elevated in Huntington's disease and AD substantia nigra\", \"pmid\": \"11071322\"},\n        {\"claim\": \"Germ-free mice show depleted AhR target genes in brain\", \"pmid\": \"31300524\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"AhR agonists (TCDD) have significant toxicity; therapeutic window unclear\", \"pmid\": \"Domain Expert assessment\"},\n        {\"claim\": \"Multiple upstream activators of IDO1; causal attribution to gut dysbiosis is speculative\", \"pmid\": \"Skeptic critique extrapolation\"}\n      ]\n    },\n    {\n      \"title\": \"Cross-Seeding: Gut Microbiome-Derived Bacterial Curli and Fungal Amyloid Synergize with Host Aβ/α-Synuclein via TLR2/TLR1 Heterodimer Signaling\",\n      \"description\": \"Commensal bacteria (E. coli, Salmonella) produce curli amyloid fibers encoded by the csg operon, while Candida and Saccharomyces produce glucan particles. These cross-seed mammalian amyloid conformations and independently engage TLR2/TLR1 heterodimers on microglia, triggering MyD88-dependent NF-κB and IRF5/IRF8 transcriptional programs that polarize microglia toward disease-associated microglia (DAM) phenotype. This paradoxically fails to clear amyloid and promotes pro-inflammatory cytokine release. SCFAs suppress IRF5 via GPR41/GPR43 and HDAC inhibition.\",\n      \"target_gene\": \"TLR2, TLR1, IRF5, IRF4, CsgA, csgABC operon\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.48,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.58,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.52,\n        \"reproducibility\": 0.48\n      },\n      \"composite_score\": 0.54,\n      \"evidence_for\": [\n        {\"claim\": \"E. coli curli accelerates α-synuclein aggregation and PD-like pathology in rats\", \"pmid\": \"30796814\"},\n        {\"claim\": \"Curli stimulates TLR2-dependent TNF-α in macrophages\", \"pmid\": \"16709925\"},\n        {\"claim\": \"IRF5 defines pro-inflammatory microglia; IRF4 promotes homeostasis\", \"pmid\": \"26900763\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TLR2/TLR1 targeting is mechanistically overlapping with H3; redundancy suggests polypharmacology rather than selective target\", \"pmid\": \"Integrated analysis\"},\n        {\"claim\": \"csg operon expression in human gut microbiome is highly variable; standardization challenges\", \"pmid\": \"Domain Expert extrapolation\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"GPR43\", \"target_type\": \"gene\", \"relation\": \"ligands_via_SCFA_deficiency\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"HDAC3\", \"target_type\": \"gene\", \"relation\": \"derepressed_by_SCFA_deficiency\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"NFKB1\", \"target_type\": \"gene\", \"relation\": \"hyperactivated_by_loss_of_inhibitory_checkpoint\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"IL1B\", \"target_type\": \"gene\", \"relation\": \"derepressed_transcription_target\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"TLR4\", \"target_type\": \"gene\", \"relation\": \"activated_by_translocated_LPS\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"MYD88\", \"target_type\": \"gene\", \"relation\": \"signaling_downstream_of_TLR4\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"CCL2\", \"target_type\": \"gene\", \"relation\": \"induced_by_MYD88_signaling\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"CCR2\", \"target_type\": \"gene\", \"relation\": \"mediates_monocyte_BBB_transmigration\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"TLR2\", \"target_type\": \"gene\", \"relation\": \"activated_by_LTA_from_dysbiotic_gut\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"NFATC1\", \"target_type\": \"gene\", \"relation\": \"dephosphorylated_and_nuclear_translocated\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"PTGS2\", \"target_type\": \"gene\", \"relation\": \"upregulated_by_NFAT_and_TLR2_signaling\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"C3\", \"target_type\": \"gene\", \"relation\": \"produced_by_primed_astrocytes\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"HDAC3\", \"target_type\": \"gene\", \"relation\": \"derepressed_by_SCFA_deficiency\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"TREM2\", \"target_type\": \"gene\", \"relation\": \"epigenetically_downregulated_by_HDAC3\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"PGC1A\", \"target_type\": \"gene\", \"relation\": \"impaired_mitochondrial_biogenesis\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"NLRP3\", \"target_type\": \"gene\", \"relation\": \"primed_by_gut-derived_LPS\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"CASP1\", \"target_type\": \"gene\", \"relation\": \"activates_pyroptosis\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"GSDMD\", \"target_type\": \"gene\", \"relation\": \"cleaved_by_CASP1_executing_pyroptosis\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"IL1B\", \"target_type\": \"gene\", \"relation\": \"matured_and_released_by_pyroptosis\"},\n    {\"source_id\": \"H5\", \"source_type\": \"hypothesis\", \"target_id\": \"C3\", \"target_type\": \"gene\", \"relation\": \"upregulated_by_IL1B_on_neurons\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"H2\", \"target_type\": \"hypothesis\", \"relation\": \"SCFA_deficiency_underlies_both_mechanisms\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"H5\", \"target_type\": \"hypothesis\", \"relation\": \"SCFAs_regulate_inflammasome_via_GPR41_GPR43\"},\n    {\"source_id\": \"H4\", \"source_type\": \"hypothesis\", \"target_id\": \"H1\", \"target_type\": \"hypothesis\", \"relation\": \"HDAC3_downstream_of_SCFA_deficiency\"},\n    {\"source_id\": \"H3\", \"source_type\": \"hypothesis\", \"target_id\": \"H5\", \"target_type\": \"hypothesis\", \"relation\": \"C3_complement_convergence_point\"},\n    {\"source_id\": \"H2\", \"source_type\": \"hypothesis\", \"target_id\": \"H5\", \"target_type\": \"hypothesis\", \"relation\": \"LPS_priming_signal_for_NLRP3\"},\n    {\"source_id\": \"H7\", \"source_type\": \"hypothesis\", \"target_id\": \"H3\", \"target_type\": \"hypothesis\", \"relation\": \"curli_LTA_both_signal_via_TLR2\"},\n    {\"source_id\": \"H1\", \"source_type\": \"hypothesis\", \"target_id\": \"H4\", \"target_type\": \"hypothesis\", \"relation\": \"butyrate_dual_mechanism_GPR_and_HDAC\"}\n  ],\n  \"synthesis_summary\": \"The integration of mechanistic hypotheses reveals that gut microbiome dysbiosis drives neuroinflammation and neurodegeneration through at least three convergent pathways, with SCFA deficiency (H1) emerging as the most evidence-supported and therapeutically actionable mechanism. H1 benefits from germ-free mouse rescue data demonstrating microglial maturation defects rescued by SCFA supplementation, and implicates dual inhibitory checkpoints on NF-κB via GPR43/GPR41 receptor activation and HDAC inhibition. H2 (leaky gut/TLR4/MyD88) ranks second with strong clinical evidence in PD patients but faces significant translational barriers including failed TLR4 antagonist trials and the paradox of enhanced neuroinflammation in germ-free mice. The mechanistic interconnections reveal that SCFA deficiency (H1) sits upstream of H4 (HDAC3/TREM2) and H5 (NLRP3 inflammasome), while LPS translocation (H2) provides the priming signal for NLRP3 activation. Critically, the domain expert feasibility analysis identifies that all hypotheses face a fundamental pharmacological challenge: no pathway has an established regulatory pathway for gut-microbiome-CNS interventions, and the germ-free mouse-to-adult-human translation gap is substantial. H1 and H2 represent the most pragmatic development paths—H1 via GPR43 agonists and HDAC3 inhibitors, H2 via gut-restricted tight junction modulators like larazotide—but require biomarker validation and regulatory precedent before clinical registration trials can proceed.\"\n}",
  "tokens_used": "4894",
  "persona_id": "persona-synthesizer"
}